1stOncology™: Cancer Intelligence Service – Page 12315 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Leap Therapeutics to Present at Cowen 40th Annual Health Care Conference

On February 26, 2020 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, Douglas E. Onsi, Chief Financial Officer, and Cynthia Sirard, MD, Vice President, Clinical Research & Development, will present a corporate overview at the Cowen 40th Annual Health Care Conference, being held in Boston on March 2-4, 2020 (Press release, Leap Therapeutics, FEB 26, 2020, https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-cowen-40th-annual-health-care-conference-301011310.html [SID1234554840]). The presentation will be followed by a 30-minute breakout session.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Leap Presentation and Breakout Session Details:

Cowen 40th Annual Health Care Conference
Date: Wednesday, March 4, 2020
Presentation Time: 8:40 a.m. Eastern Time
Breakout Session Time: 9:20 a.m. Eastern Time

The presentation will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference

On February 26, 2020 Ardelyx, Inc. (NASDAQ: ARDX) reported that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET on Wednesday, March 4, 2020 in Boston, MA (Press release, Ardelyx, FEB 26, 2020, View Source [SID1234554839]).

To access the live webcast of Ardelyx’s presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

On February 26, 2020 Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, reported that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020, at 9:20 a.m. ET (Press release, Insmed, FEB 26, 2020, View Source [SID1234554838]).

The presentation will be webcast live and can be accessed by visiting the investor relations section of the company’s website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.

Thermo Fisher Scientific President and Chief Executive Officer Marc N. Casper Elected Chairman of the Board of Directors

On February 26, 2020 Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, reported that its board of directors has elected president and chief executive officer Marc N. Casper, 51, as chairman, effective immediately (Press release, Thermo Fisher Scientific, FEB 26, 2020, View Source [SID1234554837]). Casper will continue in his role as president and chief executive officer, which he has held since October 2009.

The company also announced that Thomas Lynch, 65, has been elected lead independent director, effective immediately. Lynch has been a member of Thermo Fisher’s board since May 2009.

Casper succeeds Jim Manzi, 68, who has served as a director since May 2000 and as chairman of the board for 15 years. Manzi will continue to serve as a director on the Thermo Fisher board.

"Marc has demonstrated exceptional leadership of Thermo Fisher Scientific, driving the outstanding execution of a growth strategy that has resulted in significant value creation for our customers, colleagues and shareholders," said Manzi. "Given his contributions to the company’s success, and his insights and expertise as a member of the board, we unanimously selected Marc to also take on the chairman role as Thermo Fisher begins the next decade."

"I am honored to be taking on this additional role at such an exciting time for our company," said Casper. "Together with the board, our leadership team and our 75,000 colleagues around the world, we will continue to execute our proven strategy to create value for all those who have a stake in our success."

Casper continued, "I’ve had the pleasure of knowing and working with Tom for some time, and our board has the highest confidence in him as our lead independent director. He has brought valuable perspective to our board over the last 10 years and we look forward to continuing to benefit from his outstanding leadership skills, financial expertise and international experience."

Lynch has served as chairman of TE Connectivity Ltd. (formerly Tyco Electronics Ltd.), a global industrial technology company, since 2013 and as chief executive officer from January 2006 to March 2017. Prior to that, Lynch was president of Tyco Engineered Products & Services. He previously served as executive vice president of Motorola and president and chief executive officer of Motorola’s Personal Communications sector. Lynch’s board-level experience also includes his current roles as a director of Automated Data Processing Inc. and Cummins Inc.

Cellular Biomedicine Group to Report Fourth Quarter and Full Year 2019 Results on February 28, 2020

On February 26, 2020 Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported that it will release its financial results for the fourth quarter and full year ended December 31, 2019 after the market closes on Friday, February 28, 2020 (Press release, Cellular Biomedicine Group, FEB 26, 2020, View Source [SID1234554836]).

The Company will host a conference call and webcast with the investment community on Friday, February 28th at 4:30 p.m. Eastern Time, featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

What:

Cellular Biomedicine Fourth Quarter and Full Year 2019 Results Conference Call

Date:

Friday, February 28, 2020

Time:

4:30 p.m. Eastern Time

Live Call:

Toll-Free: 1-877-423-9813

International: 1-201-689-8573

Webcast:

View Source

Replay:

Toll-Free: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 13699688

(Available approximately two hours after the completion of the live call until 11:59 p.m. ET on March 13, 2020)